News


All series


All News

Single-agent ivosidenib (Tibsovo) has received FDA approval for the first-line&nbsp;treatment of adult patients with <em>IDH1</em>-mutant acute myeloid leukemia, as detected by an FDA-approved test, who are &ge;75 years old or are ineligible to receive intensive chemotherapy.

Combining&nbsp;lenalidomide with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone did not improve progression-free survival compared with placebo and R-CHOP as a frontline therapy in patients with activated B-cell-type diffuse large B-cell lymphoma, missing the primary endpoint of the phase III ROBUST trial.

The National Community Oncology Dispensing Association has announced the addition of hematologist and medical oncologist Barry D. Brooks, MD, to its executive council in April.